

The genes linked to human disease number in the thousands — but in all but a few hundred cases, researchers don’t understand the structure or activity of the proteins these genes encode, and therefore don’t have the data they need for traditional drug design. Atomwise uses convolutional neural networks, similar to those used in speech recognition or computer vision, to screen billions of synthesizable small molecules for those that might interact with target proteins, even without full structure data.
News & Insights

Thoughts

Thoughts
Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech

News
Data Collective Tops Up Previously Closed Fifth and Sixth Funds for a New Total of $387 Million

Thoughts
Big Data Strikes Back: The Rise of Image, Sensor, and Genome Data Powering Deep Vertical Startups
In The Media
TechCrunch
Atomwise Raises $123m Series B For Breakthrough Drug Discovery Platform
Atomwise
BioSpace
Atomwise Announces Three More Drug Discovery Partnerships – Driving $6b total value contracts in last 9 months
Atomwise
Newsweek
Newsweek talks to Atomwise CEO Abraham Heifets About His Moonshot – Using AI to Discover Better & Safer Drugs for Cancer Patients
Atomwise
Fierce Biotech
AI-driven drug discovery startup Atomwise raises $45M series A
Atomwise